BioLASCO Business Summary

BioLASCO Taiwan Co., Ltd. (6662.TWO) is the premier commercial provider of Specific Pathogen Free (SPF) laboratory rodents and preclinical research solutions in the Asia-Pacific region. The company generates revenue through three primary segments: the production and sale of standardized animal models (mice and rats), the distribution of high-end laboratory equipment and consumables (such as housing systems and diagnostic kits), and the provision of contract research services including pathology, toxicology, and serological testing. As a long-term strategic partner and licensee of Charles River Laboratories (CRL), BioLASCO integrates international breeding standards with localized logistics to serve pharmaceutical firms, CROs, and academic institutions. In the competitive landscape, BioLASCO competes with global leaders such as Inotiv (Envigo) and The Jackson Laboratory, as well as regional players like GemPharmatech and Cyagen Biosciences, maintaining a dominant market share in Taiwan while expanding its footprint through hubs in Thailand and India. The company was founded in 2001 by Chairman Colin Chen (Chen-Hsiung Chen), a veteran of the Taiwanese biotechnology sector who previously established Tseng Hsiang Life Science and pioneered the introduction of standardized laboratory animal science to the local market. The current executive leadership includes General Manager Hank Chen (Yong-Hao Chen), who oversees operational strategy and the company’s international expansion. The management team is supported by a stable board of directors with an average tenure exceeding eight years, including industry experts such as Feng Chi Cheng and Li Chu Wu. BioLASCO’s technical pedigree is anchored in its decades-long collaboration with Charles River Laboratories, ensuring its facilities maintain AAALAC international accreditation and adhere to rigorous global quality control protocols for biomedical research.